Do Causes Influence Functional Aspects and Quality of Life in Patients with Nonfibrocystic Bronchiectasis?

Table 1

Baseline clinical, etiologic, functional, and quality of life data of patients with bronchiectasis.

Variables
Clinical and etiologic data
Sex
Female	96 (57)
Male	71 (43)
Age (years)
BMI (kg/m^2)
Symptoms
Dry cough, yes	34 (26.6)
Productive cough, yes	71 (55.9)
Wheezing, yes	87 (68.0)
Smoking history, yes
Former smokers, yes	55 (32.9)
Current smokers, yes	6 (3.6)
Wood stove exposure, yes	67 (45.0)
Causes
Postinfectious	39 (23.4)
Ciliary dyskinesia	32 (19.2)
COPD	29 (17.4)
Immunodeficiency	13 (7.8)
Idiopathic	30 (18.0)
Other causes	24 (14.4)
No. of exacerbations, mean per year ()
Comorbidities, (%)
Systemic arterial hypertension (SAH), yes	72 (43.4)
Diabetes mellitus, yes	34 (20.7)
Dyslipidemia, yes	26 (15.8)
Charlson’s comorbidity index (CCI)
Drug treatment
ICS	116 (73.0)
Systemic corticosteroid	11 (6.9)
LABA	43 (27.0)
SABA	19 (11.9)
LAMA	67 (42.1)
SAMA	9 (5.7)
Macrolide	58 (36.5)
Home oxygen therapy, yes	24 (14.8)
Tomographic findings ()^#
No. of pulmonary lobes affected, (%)
1 to 3 lobes	38 (25.7)
4 to 6 lobes	110 (74.3)
Emphysema	15 (10.1)
Air trapping ()	102 (82.9)
FACED score ()
Light (0-2 points)	70 (47.3)
Moderate (3-4 points)	55 (37.2)
Severe (5-7 points)	23 (15.5)
Functional data
SpO2 (%)
Lung function ()
FVC (L)
FVC (% of predicted value)
FEV1 (L)
FEV1 (% of predicted value)
FEV1/FVC
Obstructive ventilatory disturb, yes	6 (3.8)
Obstructive ventilatory disturb with reduced FVC, yes	30 (18.9)
Preserved ratio impaired spirometry, yes	66 (41.5)
Restrictive ventilatory disturb, yes	14 (8.8)
6MWT ()
Walking distance (6MWD) (m)
6MWD as % of predicted value according to different prediction equations
Enright and Sherril [11]
Iwama et al. [12]
Soares and Pereira [13]
Saint George’s Hospital Questionnaire (SGRQ)
Symptom
Activity
Psychosocial impact
Total

Values expressed as deviation or as measures of frequency, as appropriate. See details in the text. Air trapping was analyzed only in scans with an expiratory phase. ^#In 19 patients, the images could not be recovered for prospective analysis. BMI: body mass index; CCI: Charlson’s comorbidity index (0-37); ICS: inhaled corticosteroid; LABA: long-acting beta agonist; SABA: short-acting beta agonist; LAMA: long-acting muscarinic antagonist; SAMA: short-acting muscarinic antagonist; SpO₂: peripheral oxygen saturation; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; SGRQ: Saint George’s Hospital Questionnaire, scores presented as mean and SD (range 0-100).